title: [Experience of oral hormone-chemotherapy in prostatic cancer].
abstract: Two oral anticancer agents, cyclophosphamide and UFT (mixture of futraful and uracil), were combined with hormone therapy for 42 patients with prostatic cancer. Although UFT could be taken for long periods, cyclophosphamide arose many problems such as the bone marrow suppression and gastrointestinal disturbances. The median length of the days they could take cyclophosphamide was sixty days. The survival rate of patients who were newly diagnosed and treated with this regimen was better than patients received hormone therapy only, and it suggests the possibility of the combined chemotherapy to inhibit the progression frequently observed after conventional hormone therapy.
authors.affiliation: Dept. of Urology, National Medical Center.
authors.forename: K
authors.initials: K
authors.lastname: Fujita
authors.forename: A
authors.initials: A
authors.lastname: Munakata
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage
chemical_list: D005641:Tegafur; D014498:Uracil; D003520:Cyclophosphamide